ICER Suggests Big Price Cut For Novartis’s New PNH Drug

Novartis AG would have to drop the list price of Fabhalta (iptacopan) for paroxysmal nocturnal hemoglobinuria (PNH) by nearly three quarters to make it more cost-effective, as much of its price is driven by the high prices of the anti-C5 inhibitors used for PNH, according to a new report by the Institute for Clinical and Economic Review (ICER), which also recommended a lower list price for AstraZeneca PLC’s danicopan.